SAB Biotherapeutics (SABS) vs X4 Pharmaceuticals (XFOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
SAB Biotherapeutics (SABS) has outperformed X4 Pharmaceuticals (XFOR) over the past year, gaining 23.1% versus a loss of 18.3%. Over five years, SABS leads with a -97.1% price change compared with -98.2% for XFOR. X4 Pharmaceuticals is the larger company by market cap ($278.6 million vs $262.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SABS | XFOR |
|---|---|---|
| Share price | $2.88 | $2.81 |
| Market cap | $262.04M | $278.60M |
| 1-day change | -1.71% | +1.44% |
| YTD return | -22.99% | -29.75% |
| 1-year return | +23.08% | -18.31% |
| 5-year return | -97.15% | -98.21% |
| P/E ratio (TTM) | — | 140.50 |
| EPS (TTM) | $-1.27 | $0.02 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.15 | $4.83 |
| 52-week low | $2.10 | $2.70 |
| Distance from 52-week high | -44.08% | -41.82% |
| Analyst consensus | none | none |
| Avg. price target upside | +304.17% | +312.81% |
| Average volume | 486.82K | 849.98K |
| Shares outstanding | 90.99M | 99.15M |
| Employees | 86 | 45 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SABS has outperformed XFOR by 41.4 percentage points over the past year.
About SAB Biotherapeutics
SABS stock →SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials.
Healthcare · Biotechnology · 86 employees
About X4 Pharmaceuticals
XFOR stock →X4 Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases of the immune system. It offers XOLREMDI, an orally small-molecule selective antagonist of chemokine receptor CXCR4, which is in phase 3 clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome.
Healthcare · Biotechnology · 45 employees
SABS vs XFOR FAQ
Which is bigger, SAB Biotherapeutics or X4 Pharmaceuticals?
X4 Pharmaceuticals (XFOR) is larger, with a market capitalization of $278.60M compared with $262.04M for SAB Biotherapeutics (SABS).
Which stock has performed better over the past year, SABS or XFOR?
SABS returned +23.08% over the past 12 months, compared with -18.31% for XFOR (price return, excluding dividends). Past performance does not predict future results.
Are SAB Biotherapeutics and X4 Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.